DIPIVEFRIN HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIPIVEFRIN HYDROCHLORIDE (DIPIVEFRIN HYDROCHLORIDE).
DIPIVEFRIN HYDROCHLORIDE is a prodrug of epinephrine. It is hydrolyzed by esterases in the eye to epinephrine, which stimulates alpha- and beta-adrenergic receptors, reducing aqueous humor production and increasing outflow, thereby lowering intraocular pressure.
| Metabolism | Hydrolyzed by esterases in the eye to epinephrine; epinephrine is further metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). |
| Excretion | Dipivefrin is rapidly hydrolyzed to epinephrine by esterases in the eye and systemically. The primary route of elimination is renal excretion of metabolites (epinephrine and its conjugates), accounting for >90% of the dose. Minimal biliary/fecal elimination (<5%). |
| Half-life | The terminal elimination half-life of dipivefrin is approximately 1–2 hours. However, its active metabolite, epinephrine, has a short half-life of ~2 minutes. Clinical effect correlates with ocular tissue concentrations rather than plasma levels. |
| Protein binding | Dipivefrin itself is not significantly protein bound (<10%). However, its active metabolite epinephrine is ~50% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | The apparent volume of distribution (Vd) for dipivefrin is not well characterized due to rapid hydrolysis. For epinephrine, Vd is 0.2–0.4 L/kg, reflecting distribution predominantly into extracellular fluid. |
| Bioavailability | Ophthalmic (topical): Systemic bioavailability after ocular instillation is very low (<1%) due to extensive local hydrolysis and minimal absorption. Oral administration is not clinically used. |
| Onset of Action | Ophthalmic (topical): Onset of intraocular pressure reduction occurs within 30 minutes, with peak effect at 1–2 hours. |
| Duration of Action | Ophthalmic (topical): Duration of intraocular pressure reduction is 12–24 hours with twice-daily dosing. Clinical note: Effects may persist longer in some patients due to ocular tissue retention. |
One drop of 0.1% solution in each eye twice daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No adjustment required. |
| Liver impairment | No adjustment required. |
| Pediatric use | Not recommended; safety and efficacy not established. |
| Geriatric use | Use with caution; monitor for systemic effects due to possible increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIPIVEFRIN HYDROCHLORIDE (DIPIVEFRIN HYDROCHLORIDE).
| Breastfeeding | No human data on excretion in breast milk. Dipivefrin is a prodrug of epinephrine; epinephrine is excreted in milk but with low oral bioavailability. M/P ratio unknown. Use with caution only if clearly needed. |
| Teratogenic Risk | Insufficient human data; animal studies not available. Avoid in first trimester unless benefit outweighs risk. Fetal bradycardia and reduced uterine blood flow potential due to alpha-adrenergic activity. Increased risk of fetal hypoxia if maternal hypertension controlled. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to dipivefrin or epinephrine","Narrow-angle glaucoma","Aphakia (relative contraindication)"]
| Precautions | ["May cause macular edema in aphakic patients","May exacerbate narrow-angle glaucoma","May cause cardiovascular effects (e.g., hypertension, arrhythmias) in susceptible patients","May cause rebound hyperemia and allergic reactions","Use with caution in patients with hypertension, hyperthyroidism, or cardiac disease"] |
| Food/Dietary | No significant food interactions. Avoid excessive caffeine or stimulants that may potentiate adrenergic effects. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, heart rate, intraocular pressure. Fetal heart rate monitoring in third trimester if used systemically. Assess for maternal palpitations or tremor. |
| Fertility Effects | No known impact on fertility in humans. Epinephrine derivatives may impair uterine blood flow but not directly affect fertility. |
| Dipivefrin is a prodrug of epinephrine, enhancing corneal penetration. Onset of IOP reduction occurs within 30 minutes, peak effect at 1-2 hours. Caution in patients with narrow-angle glaucoma; can precipitate angle closure. Monitor for systemic adrenergic effects (tachycardia, hypertension) in susceptible patients. Contraindicated in patients using MAOIs or tricyclic antidepressants due to risk of hypertensive crisis. |
| Patient Advice | Instill one drop in the affected eye(s) every 12 hours, usually in the morning and at bedtime. · Wash hands before use. Tilt head back, pull down lower eyelid, and apply drop without touching the eye or eyelid. · After instillation, close eyes and press on the inner corner of the eye (nasolacrimal occlusion) for 1-2 minutes to reduce systemic absorption. · Do not use while wearing soft contact lenses; remove lenses before instillation and wait at least 15 minutes before reinserting. · May cause temporary blurred vision, burning, or stinging upon instillation. If ocular pain or visual changes occur, contact your doctor. · Report symptoms of systemic effects such as rapid heartbeat, palpitations, headache, or tremor. · Do not discontinue abruptly; use regularly as prescribed even if symptoms improve. |